Stock of the Day
January 3, 2025

Anebulo Pharmaceuticals (ANEB)

$1.55

-$0.07 (--4.6%)

Market Cap: 40.07M

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.

Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Recent News

3 US Penny Stocks With Market Caps Under $800M (uk.finance.yahoo.com)
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Director Purchases $9,999,999.90 in Stock (insidertrades.com)
Anebulo Pharmaceuticals collaborates with FDA to advance selonabant (finance.yahoo.com)
Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise (businesswire.com)
Anebulo Pharmaceuticals Advances Cannabis Toxicity Solutions (tipranks.com)
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates (finance.yahoo.com)
Benchmark maintains Speculative Buy on Anebulo stock (uk.investing.com)
Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock Rating Reaffirmed by Benchmark (marketbeat.com)
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates (finance.yahoo.com)
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Up 12.8% in August (marketbeat.com)